Svante and Tenaska Forge Collaboration to Deliver Fully Integrated Carbon Capture and Storage Solutions
16.1.2025 16:03:00 EET | Business Wire | Press release
Svante Technologies Inc. (Svante), a leading innovator in carbon capture and removal technology, and Tenaska, a prominent CO2 transportation and sequestration service provider, have signed a Memorandum of Understanding (MOU) to collaborate on delivering cost-effective, integrated solutions for industrial carbon capture and storage (CCS). This collaboration represents a significant step toward addressing global industrial emissions and advancing the decarbonization of many industrial sectors, including pulp & paper, cement, steel, oil & gas, and more.
Under the terms of the non-exclusive MOU, Svante and Tenaska will combine their technology and services to provide end-to-end CCS value chain solutions to select customers. Svante’s cutting-edge solid sorbent-based carbon capture technology will facilitate efficient, environmentally responsible CO2 capture, while Tenaska will provide regional planning and infrastructure for CO2 transportation and storage. Tenaska is advancing a platform of mid- and early-stage projects in strategic locations across the United States, with Class VI permit applications filed for nearly 20 injection wells across multiple states.
Together, the companies aim to simplify the path to decarbonization for industrial emitters worldwide.
Key Objectives of the Collaboration:
- Integrated Carbon Management Solutions:
- Svante will focus on capturing CO2 emissions at industrial facilities, including related processes such as CO2 compression, conditioning, and liquefaction.
- Tenaska will manage CO2 transportation and sequestration, ensuring safe, secure, permanent storage deep underground.
- North America-wide Outreach and Customer Engagement:
- The joint initiative will actively promote carbon capture and storage to industrial emitters across North America, offering tailored solutions to meet diverse needs.
- Innovative Project Development:
- The collaboration will identify and assess commercially viable opportunities for CCS, leveraging the combined technical and operational expertise of both organizations.
Leadership Quotes:
“This collaboration is well aligned with Svante’s mission to make carbon capture accessible for industries worldwide,” said Matt Stevenson, Chief Revenue Officer of Svante. “By combining our technology with Tenaska’s extensive experience in CO2 transportation and storage, we can offer end-to-end solutions that accelerate the transition to a net-zero future.”
“Recognizing the synergies with our CCS development platform, Tenaska is proud to work with Svante to advance innovative solutions for carbon management,” said Bret Estep, Vice President, Tenaska Development. “Together, we aim to provide industrial customers with the tools and confidence to achieve their decarbonization goals.”
A Vision for the Future
The Svante-Tenaska collaboration underscores a shared commitment to providing business solutions that help industrial sectors reduce carbon emissions. By offering integrated, efficient, and scalable CCS solutions, the companies aim to unlock new opportunities for industries to meet their sustainability targets while maintaining operational excellence.
About Svante
Svante is a purpose-driven, leading carbon capture and removal solutions provider. The Vancouver, Canada-based company manufactures nanoengineered filters and modular rotary contactor machines that capture and remove CO2 from industrial emissions and the air in an environmentally responsible manner. Svante is on the 2024 Global Cleantech 100, the XPRIZE Foundation’s XB100 – World’s Top 100 Deep Tech Companies and was ranked second among private companies in the Corporate Knights’ Future 50 Fastest Growing Sustainable Companies. For more information, visit www.svanteinc.com and follow Svante on LinkedIn at www.linkedin.com/svantesolutions.
About Tenaska
Consistently ranked among Forbes’ List of America’s Largest Private Companies, Tenaska is a leading energy company with business operations that span the energy value chain. Tenaska Marketing Ventures (TMV) and Tenaska Power Services Co. (TPS) are among the largest natural gas and electric power marketing companies in North America. The company has an operating fleet of 7,460 megawatts (MW) of natural gas and renewable generating facilities and throughout its history has developed, managed and/or operated approximately 22,000 MW of natural gas-fueled and renewable generation. Tenaska is actively developing 10 carbon sequestration projects capable of storing more than 50 million metric tons of CO2 per year, multiple natural gas-fueled generation projects and a development services portfolio of more than 35,000 MW of solar, wind, energy storage and green hydrogen projects. Tenaska seeks investment opportunities to allocate its capital into generation assets nationwide. For more information, visit www.tenaska.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250116961790/en/
Contacts
Media Contacts:
Svante:
Colleen Nitta
Director of Marketing and Communications
604-970-2813
cnitta@svanteinc.com
Tenaska:
Timberly Ross
Senior Director, Community Relations
402-691-9517
tross@tenaska.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release
Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom